TABLE 1.
Characteristics of the study cohorta
| Subject | Age (yr) | Sex | Race | CD4 count | CD4 percent (%) | HIV RNA (copies/ml of plasma) | ARV therapy | Duration (mo)b |
|---|---|---|---|---|---|---|---|---|
| TCH-015 | 11 | F | Latino | 1,166 | 39 | 30 | HAART | 13 |
| TCH-027 | 11 | M | Cauc | 1,325 | 36 | <50 | HAART | 17 |
| TCH-060 | 11 | F | AA | 496 | 28 | <50 | HAART | 3 |
| TCH-061 | 17 | F | Cauc | 1,078 | 44 | <50 | HAART | 8 |
| TCH-063 | 9 | F | Latino | 992 | 41 | <50 | HAART | 54 |
| TCH-064 | 14 | M | Cauc | 780 | 23 | <50 | HAART | 13 |
| TCH-066 | 9 | F | Cauc/AA | 1,079 | 31 | <50 | DDI | 8 |
| TCH-067 | 10 | F | AA | 1,049 | 38 | <50 | HAART | 35 |
| TCH-073 | 10 | F | Cauc | 1,110 | 32 | <50 | HAART | 43 |
| TCH-080 | 10 | F | Cauc | 1,252 | 28 | <50 | HAART | 21 |
| TCH-014 | 14 | F | Cauc/AA | 828 | 36 | 70 | HAART | 8 |
| TCH-017 | 12 | F | AA | 563 | 28 | 830 | None | NA |
| TCH-043 | 9 | M | AA | 1,181 | 32 | 200 | AZT/DDI | 89 |
| TCH-045 | 8 | F | Haitian | 1,406 | 33 | 42,000 | None | NA |
| TCH-065 | 10 | F | AA | 961 | 46 | 120 | HAART | 56 |
| TCH-068 | 6 | F | Cauc | 874 | 23 | 79 | AZT/DDI | 21 |
| TCH-069 | 7 | F | AA | 2,272 | 26 | 3400 | AZT/3TC | NA |
| TCH-077 | 16 | M | Cauc | 432 | 24 | 13,000 | HAART | NA |
Age, sex, race, HIV RNA measurement, CD4 data, and treatment status are displayed for the 18 perinatally infected children comprising the study cohort. For subjects with undetectable viremia, the duration of viral suppression is expressed as the number of months since the viral load fell below 400 copies/ml, since many subjects did not have measurements obtained by using ultrasensitive assays. HAART regimens varied by subject, but all consisted of at least three drugs, including a protease inhibitor and/or a nonnucleoside reverse transcriptase inhibitor. F, female; M, male; Cauc, Caucasian; AA, African-American; ARV, antiretroviral; DDI, didauosine; AZT, zidovudine; 3TC, lamivudine; NA, not applicable.
That is, once the viral load fell below 400 copies/ml.